Given that PI3K-AKT-mTOR pathway has been proven to be dysregulated via several genetic mechanisms, among them mutations of the PTEN [65], combination therapy of ICB with PI3K-AKT pathway inhibitors may have a role in the treatment of certain sarcomas [63,66,67]. The gene discussed is PTEN; the disease is sarcoma.